184 related articles for article (PubMed ID: 36139117)
1. Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study.
Islam MA; Barshetty MM; Srinivasan S; Dudekula DB; Rallabandi VPS; Mohammed S; Natarajan S; Park J
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139117
[TBL] [Abstract][Full Text] [Related]
2. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
Ahmad MF; Alam I; Huff SE; Pink J; Flanagan SA; Shewach D; Misko TA; Oleinick NL; Harte WE; Viswanathan R; Harris ME; Dealwis CG
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8241-8246. PubMed ID: 28716944
[TBL] [Abstract][Full Text] [Related]
3. De novo design based identification of potential HIV-1 integrase inhibitors: A pharmacoinformatics study.
Shinde PB; Bhowmick S; Alfantoukh E; Patil PC; Wabaidur SM; Chikhale RV; Islam MA
Comput Biol Chem; 2020 Oct; 88():107319. PubMed ID: 32801062
[TBL] [Abstract][Full Text] [Related]
4. Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase.
Iman M; Khansefid Z; Davood A
Recent Pat Anticancer Drug Discov; 2016; 11(4):461-468. PubMed ID: 27670694
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
Huff SE; Mohammed FA; Yang M; Agrawal P; Pink J; Harris ME; Dealwis CG; Viswanathan R
J Med Chem; 2018 Feb; 61(3):666-680. PubMed ID: 29253340
[TBL] [Abstract][Full Text] [Related]
6. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
7. Identification of Potential Cytochrome P450 3A5 Inhibitors: An Extensive Virtual Screening through Molecular Docking, Negative Image-Based Screening, Machine Learning and Molecular Dynamics Simulation Studies.
Islam MA; Dudekula DB; Rallabandi VPS; Srinivasan S; Natarajan S; Chung H; Park J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012627
[TBL] [Abstract][Full Text] [Related]
8. Insight into the screening of potential beta-lactamase inhibitors as anti-bacterial chemical agents through pharmacoinformatics study.
Parida P; Bhowmick S; Saha A; Islam MA
J Biomol Struct Dyn; 2021 Feb; 39(3):923-942. PubMed ID: 31984863
[TBL] [Abstract][Full Text] [Related]
9. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.
Kitamura T; Srivastava J; DiGiovanni J; Kiguchi K
Mol Carcinog; 2015 Jun; 54(6):459-72. PubMed ID: 24839254
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
Tripathy S; Azam MA; Jupudi S; Sahu SK
J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
Huff SE; Winter JM; Dealwis CG
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
[TBL] [Abstract][Full Text] [Related]
12. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.
Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J
J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340
[TBL] [Abstract][Full Text] [Related]
13. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.
Misko TA; Liu YT; Harris ME; Oleinick NL; Pink J; Lee HY; Dealwis CG
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):438-450. PubMed ID: 30734609
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoinformatics-based identification of anti-bacterial catalase-peroxidase enzyme inhibitors.
Jangam CS; Bhowmick S; Chorge RD; Bharatrao LD; Patil PC; Chikhale RV; AlFaris NA; ALTamimi JZ; Wabaidur SM; Islam MA
Comput Biol Chem; 2019 Dec; 83():107136. PubMed ID: 31630014
[TBL] [Abstract][Full Text] [Related]
15. Identification of PfENR inhibitors: A hybrid structure-based approach in conjunction with molecular dynamics simulations.
Manhas A; Patel A; Lone MY; Jha PK; Jha PC
J Cell Biochem; 2018 Nov; 119(10):8490-8500. PubMed ID: 30105881
[TBL] [Abstract][Full Text] [Related]
16. Structure-based identification of galectin-1 selective modulators in dietary food polyphenols: a pharmacoinformatics approach.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
Mol Divers; 2022 Jun; 26(3):1697-1714. PubMed ID: 34482478
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoinformatics-based identification of chemically active molecules against Ebola virus.
Islam MA; Pillay TS
J Biomol Struct Dyn; 2019 Sep; 37(15):4104-4119. PubMed ID: 30449258
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations.
Katari SK; Natarajan P; Swargam S; Kanipakam H; Pasala C; Umamaheswari A
J Recept Signal Transduct Res; 2016 Dec; 36(6):558-571. PubMed ID: 26906522
[TBL] [Abstract][Full Text] [Related]
19. Designing of benzothiazole derivatives as promising EGFR tyrosine kinase inhibitors: a pharmacoinformatics study.
Shahare HV; Talele GS
J Biomol Struct Dyn; 2020 Mar; 38(5):1365-1374. PubMed ID: 30955452
[TBL] [Abstract][Full Text] [Related]
20. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.
Qiu W; Zhou B; Darwish D; Shao J; Yen Y
Biochem Biophys Res Commun; 2006 Feb; 340(2):428-34. PubMed ID: 16376858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
